Veterinary Therapeutics最新文献

This study evaluated bacterial isolates obtained during abdominal surgery and their relationship to short-term incisional complications. Samples of peritoneal fluid and from resection and/or enterotomy sites from 49 horses were cultured, with 96% having at least one positive culture result. The most common isolates were Escherichia coli, Streptococcus spp, and Enterococcus spp. Horses with small intestinal resections were more likely to grow obligate anaerobes and enteric organisms. Horses with small intestinal lesions (+/- resection) were more likely to grow enteric organisms and less likely to grow non-enteric organisms. Horses without enterotomy or resection procedures were more likely to grow 3 isolates and did not grow obligate anaerobes. The continued incisional drainage rate was 10%. Horses with preoperative peripheral leukocyte counts >8,500 cells/ul were more likely to develop incisional drainage. Many horses undergoing abdominal surgery may have positive intraoperative culture results. Our results did not provide evidence for the routine use of intraoperative culture to predict short-term incisional complications. Further studies are needed to evaluate the value of intraoperative culture in horses at high risk for incisional complications.

In vitro activity of ceftiofur and six other antimicrobial agents was assessed for 516 Streptococcus equi subsp zooepidemicus isolates collected from horses with lower respiratory tract infections in North America in 2007 and 2008 and 239 equine S. equi subsp zooepidemicus isolates received from US and Canadian veterinary diagnostic laboratories between 1989 and 2007. The lowest concentration of ceftiofur inhibiting the growth of 90% of the isolates (MIC90) was 0.12 microg/ml for both groups of isolates. The Clinical and Laboratory Standards Institute susceptible breakpoint set for ceftiofur against this organism is a minimal inhibitory concentration value of ≤ 0.25 microg/ml. The MIC90 values remained consistent for isolates collected over 19 years.

A study was conducted in a feedlot in Alberta, Canada, to compare the clinical efficacy of a single injection of ceftiofur crystalline free acid sterile injectable suspension with three daily treatments of ceftiofur sodium sterile powder for the treatment of footrot. Use of a long-acting antimicrobial to treat footrot would reduce labor costs and hospital pen space requirements during high-risk periods. Four hundred cattle clinically diagnosed with footrot were systematically randomized to one of two treatment groups. The treatment success rate at 14 days after treatment (99.5% for ceftiofur crystalline free acid sterile injectable suspension and 99.0% for ceftiofur sodium sterile powder for injection) was not statistically different (P>.05) between the two drugs.

Spot-on formulations of metaflumizone and a combination of fipronil-(S)-methoprene were evaluated in adult cats to determine the duration of 24- and 48-hour efficacy and short-term speed of kill against adult cat fleas, Ctenocephalides felis felis. Speed of kill efficacies (at 12, 18, 24, and 48 hours) were assessed against existing (day -1) infestations and against infestations at day 7, and efficacy was assessed 24 and 48 hours after weekly flea infestations through day 42. Cats treated with fipronil-(S)-methoprene had significantly (P<.01) fewer fleas than those treated with metaflumizone at 12 and 18 hours after treatment (day 0) and on the day 7 infestations. Fipronil-(S)-methoprene-treated cats also had significantly (P<.05) fewer fleas than metaflumizone-treated cats for all 24-hour counts from initial treatment on day 0 through infestation day 42 and for the 48-hour counts on day 28 through day 42.

The pharmacokinetics of fentanyl administrated IV (0.01 mg/kg) and in a carboxymethylcellulose gel (0.05 mg/kg) applied to the buccal mucosa of six healthy adult medium- to large-breed dogs was evaluated. At 5 minutes after transmucosal (TM) administration, serum fentanyl levels above the therapeutic target (0.95 ng/ml) were achieved in all dogs. Except for the longer duration of serum fentanyl concentrations above the therapeutic target associated with TM administration, no significant pharmacokinetic differences were found between IV and TM fentanyl. TM fentanyl may be considered a noninvasive alternative to IV administration with rapid achievement of serum fentanyl concentrations.

Oral S-adenosylmethionine (SAMe) tosylate supplementation (Novifit tablets, Virbac) was evaluated as a dietary aid for the management of age-related mental impairment in dogs. Thirty-six dogs older than 8 years that had displayed signs of cognitive dysfunction for at least 1 month were selected for the study. The dogs were administered 18 mg/kg SAMe tosylate (n=17) or identical placebo tablets (n=19) for 2 months. Concurrent behavioral treatment was forbidden. A 14-item standardized questionnaire evaluated behavior and locomotion difficulties. Compared with the placebo group, SAMe-treated dogs showed greater improvement in activity (41.7% versus 2.6% after 4 weeks, P<.0003; 57.1% versus 9.0% after 8 weeks, P<.003) and awareness (33.3% versus 17.9% after 4 weeks, P<.05; 59.5% versus 21.4% after 8 weeks, P<.01). The aggregate mental impairment score was reduced by more than 50% in 41.2% and 15.8% of dogs treated with SAMe and placebo, respectively, at week 8. SAMe tosylate tablets proved safe and effective in improving signs of age-related mental decline in dogs.

Pharmacokinetic analysis of buprenorphine administered to six healthy dogs via the oral transmucosal (OTM) route at doses of 20 and 120 microg/kg was conducted using liquid chromatography-electrospray ionization-tandem mass spectroscopy (LC-ESI-MS/MS). Bioavailability was 38% plus or minus 12% for the 20 microg/kg dose and 47%+/-16% for the 120 microg/kg dose. Maximum plasma concentrations were similar for buprenorphine doses of 20 microg/kg IV and 120 microg/kg OTM. Sedation and salivation were common side effects, but no bradycardia, apnea, or cardiorespiratory depressive effects were seen. When the two OTM dosing rates were normalized to dose, LC-ESI-MS/MS analysis of buprenorphine and its metabolites detected no significant difference (P>.05), indicating dose proportionality. The results of this study suggest that OTM buprenorphine may be an alternative for pain management in dogs.

Health and feed performance parameters of 293 beef stocker calves at risk for bovine respiratory disease were compared after metaphylactic administration of one of two antimicrobials (tulathromycin or tilmicosin) with different durations of activity; the antimicrobial was administered 1 day after arrival. Calves that received metaphylactic tulathromycin displayed significant improvement in morbidity, mortality, and first-treatment success rates (P<.05) compared with tilmicosin-treated calves. Tulathromycin-treated calves also showed a significantly improved average daily gain and feed:gain ratio (P<.05) compared with tilmicosin-treated calves. Under conditions of this study, calves receiving tulathromycin were healthier through a 43-day growing phase compared with calves receiving tilmicosin. This health difference likely accounted for the differences in feed performance between the treatment groups.

Three groups of healthy dogs with low antibody titers to Bordetella bronchiseptica (Bb), canine parainfluenza virus (CPI), and canine adenovirus type 2 (CAV-2) were used in this study. One group was vaccinated with a single dose of monovalent attenuated Bb vaccine and one group with a trivalent vaccine containing attenuated Bb, CPI, and CAV-2; dogs were vaccinated intranasally with a single dose of the respective vaccines. The third group served as unvaccinated controls. All vaccinated dogs subsequently developed serum antibody titers to Bb that persisted for at least 1 year. Following Bb challenge 1 year after vaccination, all vaccinated dogs, regardless of group, showed significantly fewer clinical signs and shed significantly fewer challenge organisms than unvaccinated controls. These results demonstrate that intranasal administration of a single dose of monovalent attenuated Bb vaccine or trivalent vaccine containing attenuated Bb, CPI, and CAV-2 provides 1 year of protection against Bb.